Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Uhlig, A; Uhlig, J; Trojan, L; Woike, M; Leitsmann, M; Strauß, A.
Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer.
Future Oncol. 2021; 17(1): 45-56.
Doi: 10.2217/fon-2020-0900
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Leitsmann Marianne
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand-foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand-foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged - administration & dosage
- Axitinib - administration & dosage, adverse effects
- Carcinoma, Renal Cell - mortality, therapy
- Chemotherapy, Adjuvant - adverse effects, methods
- Disease Progression - administration & dosage
- Fatigue - chemically induced, epidemiology
- Female - administration & dosage
- Hand-Foot Syndrome - epidemiology, etiology
- Humans - administration & dosage
- Incidence - administration & dosage
- Kidney Neoplasms - mortality, therapy
- Male - administration & dosage
- Middle Aged - administration & dosage
- Nephrectomy - administration & dosage
- Pneumonia - chemically induced, epidemiology
- Prognosis - administration & dosage
- Progression-Free Survival - administration & dosage
- Prospective Studies - administration & dosage
- Protective Factors - administration & dosage
- Risk Assessment - methods, statistics & numerical data
- Sirolimus - administration & dosage, adverse effects, analogs & derivatives
- Stomatitis - chemically induced, epidemiology
- Sunitinib - administration & dosage, adverse effects
- Thrombocytopenia - chemically induced, epidemiology
- Find related publications in this database (Keywords)
- axitinib
- metastatic renal cell cancer
- overall survival
- progression-free survival
- sunitinib
- temsirolimus
- treatment side effects